Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Generate Biomedicines, Inc.NASDAQ: GENB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation of $0 in Q1 FY2026

Q1 FY2026 stock-based compensation was $0.

Context

  • Stock-based compensation amounted to 64.5% of revenue in FY2025, down 30.6 pp from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$20.58M+5.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+5.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
20.58M USD
Year-over-year change
+5.7%
1-year CAGR
+5.7%

Stock-Based Compensation vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 stock-based compensation of $20.58M is the 2nd largest of the 5 companies compared; the peer median is $12.44M.
  • Its year-over-year change of +5.7% is the highest of 5, against a peer median of -37.2%.
  • Stock-based compensation amounts to 64.5% of revenue for GENB, versus a peer median of 404.5%.
GENB Competitors Peer median
Stock-Based Compensation for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$48.87M -15.9%+4.1%72.0%
GENBGenerate Biomedicines, Inc.FY2025$20.58M +5.7%—64.5%
ABSIAbsci CorporationLTM Mar 2026$13.53M -11.4%+13.5%737.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$11.34M -79.7%-18.3%872.4%
STROSutro Biopharma, Inc.LTM Mar 2026$10.03M -58.5%-18.9%10.1%
Peer median (excluding GENB) $12.44M-37.2%-7.1%404.5%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.